Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease

Blood (2020) 136 (9): 1080–1090.

https://doi.org/10.1182/blood.2019004653

Published: 2020

Includes: Supplemental data

Journal Articles

Darbepoetin Alfa for the Treatment of Anemic Patients with Myelodysplastic Syndrome: A Belgian Single-Arm, Companion Trial to the Arcade Phase 3 Study

Michel Delforge, Dominiek Mazure, Isabelle Vande Broek, Jo Caers, Sejal Badre, Bhakti Mehta, Cisio De Oliveira Brandao

Blood (2017) 130 (Supplement 1): 5318.

https://doi.org/10.1182/blood.V130.Suppl_1.5318.5318

Published: 2017

Journal Articles

An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)

Uwe Platzbecker, MD, Argiris Symeonidis, MD PhD, Jeroen Simon Goede, Agnes Guerci-Bresler, Michel Delforge, MDPhD, Esther Natalie Oliva, MD, Jiri Mayer, Prof, MD SCs, Sejal Badre, Bhakti Mehta, Cisio De Oliveira Brandao

Blood (2017) 130 (Supplement 1): 4271.

https://doi.org/10.1182/blood.V130.Suppl_1.4271.4271

Published: 2017

Journal Articles

Erythropoiesis-Stimulating Agents in Elderly Patients with Anemia of Unknown Etiology: Treatment Response and Cardiovascular Outcomes

Zachary Gowanlock, BASc, Swetha Sriram, MD, Alison Martin, MD, Anargyros Xenocostas, MD, Alejandro Lazo-Langner, MD MSc, FRCPC

Blood (2016) 128 (22): 1267.

https://doi.org/10.1182/blood.V128.22.1267.1267

Published: 2016

Journal Articles

Treatment of a Large National Population of Anemic Hemodialysis Patients with a Long-Lasting Erythropoietin Stimulating Agent

Amanda Stennett, PhD, Norma Ofsthun, PhD, John Larkin, MS, Marta Reviriego-Mendoza, PhD, Len Usvyat, PhD, Franklin W Maddux, MD FACP, Jeffrey Hymes, MD

Blood (2016) 128 (22): 1268.

https://doi.org/10.1182/blood.V128.22.1268.1268

Published: 2016

Journal Articles

Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

Sandra Malak, MD, Pascale Cony-Makhoul, MD, Jean-Christophe Ianotto, MD, Dana Ranta, MD, Philippe Rodon, MD, Fabienne Vacheret, MD, Barraco Fiorenza, MD, Francoise Boyer, MD, Katell Le Du, MD, Loic Garcon, MD PhD, Francois Lefrere, MD, Mathieu Wemeau, MD, Valerie Ugo, MD PhD, Jean-Jacques Kiladjian, MD PhD, Lydia Roy, MD

Blood (2016) 128 (22): 3123.

https://doi.org/10.1182/blood.V128.22.3123.3123

Published: 2016

Journal Articles

A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)

Uwe Platzbecker, MD, Argiris Symeonidis, Esther N. Oliva, Jeroen S. Goede, Michel Delforge, Jiri Mayer, Borhane Slama, Sejal Badre, Eduard Gasal, Bhakti Mehta, Janet Franklin

Blood (2016) 128 (22): 2010.

https://doi.org/10.1182/blood.V128.22.2010.2010

Published: 2016

Journal Articles

Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis

Sophie Park, MD PhD, Pierre Fenaux, MD PhD, Peter Greenberg, MD, Bhakti Mehta, MD MPH, Fiona Callaghan, PhD, Christopher Kim, PhD MPH, Dianne Tomita, PhD, Hairong Xu, MD PhD

Blood (2015) 126 (23): 5236.

https://doi.org/10.1182/blood.V126.23.5236.5236

Published: 2015

Journal Articles

Validation of Predictive Models for Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndromes

Zachary Gowanlock, BASc, Swetha Sriram, MD, Alison Martin, MD, Alejandro Lazo-Langner, MD MSc

Blood (2015) 126 (23): 5246.

https://doi.org/10.1182/blood.V126.23.5246.5246

Published: 2015

Journal Articles

A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Hironori Harada, MD PhD, Hirohiko Shibayama, Jun Ho Jang, MD PhD, Ryutaro Shimazaki, Kinuko Mitani, MD, PhD, Kenichi Sawada, MD PhD, Hyeoung-Joon Kim, MD PhD

Blood (2014) 124 (21): 4642.

https://doi.org/10.1182/blood.V124.21.4642.4642

Published: 2014

Journal Articles

Incidence and Management of Hematological Toxicities Associated with Treatment of Hepatitis C Virus Infection in Cancer Patients

Andreas Kyvernitakis, MD, Thein H. Oo, MD FACP, FRCP, Michael H. Kroll, MD, Vahid Afshar-Kharghan, MD, Parag Mahale, MBBS, MPH, Harrys A. Torres, MD FACP

Blood (2014) 124 (21): 4126.

https://doi.org/10.1182/blood.V124.21.4126.4126

Published: 2014

Journal Articles

Poor ESA Responders As Defined By Week 4 Hemoglobin Response Have Greater ESA Dosing but Worse Cardiovascular Outcomes in Patients with Anemia of Chronic Kidney Disease (CKD) Not on Dialysis

Robert C. Kane, MD, Qing Xu, PhD, Rajeshwari Sridhara, PhD, Justin Earp, PhD

Blood (2014) 124 (21): 4016.

https://doi.org/10.1182/blood.V124.21.4016.4016

Published: 2014

Journal Articles

Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study

Richard Delarue, MD, Herve Tilly, MD, Gilles Andre Salles, MD, PhD, Catherine Thieblemont, MD, PhD, Serge Bologna, MD, Herve Ghesquieres, MD, PhD, Olivier Hermine, MD, PhD, Corinne Haioun, MD, Andre Bosly, MD, PhD

Blood (2013) 122 (21): 2202.

https://doi.org/10.1182/blood.V122.21.2202.2202

Published: 2013

Journal Articles

Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study

Blood (2013) 122 (21): 3663.

https://doi.org/10.1182/blood.V122.21.3663.3663

Published: 2013

Journal Articles

The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Mary Frances McMullin, MD, Claire N Harrison, DM FRCP FRCPath, Dietger Niederwieser, Hilde Demuynck, Nadja Jakel, Andres Sirulnik, MD, PhD, Mari McQuity, RN, MPH, Viktoriya Stalbovskaya, PhD, Christian Recher, MD, Koen Theunissen, MD, Heinz Gisslinger, MD, Jean-Jacques Kiladjian, MD, PhD, Haifa-Kathrin Al- Ali

Blood (2012) 120 (21): 2838.

https://doi.org/10.1182/blood.V120.21.2838.2838

Published: 2012

Journal Articles

Correction of Anemia in the Frail Elderly (CAFÉ): Results of a Randomized, Double-Blind, Placebo-Controlled Study with Darbepoetin Alfa in Elderly Patients with Chronic Unexplained Anemia

Arturo Loaiza-Bonilla, MD, Andrew Artz, MD MS, Francis Salerno, MD, Sean X Leng, MD, PhD, Shing-Shing Yeh, MD, Rex Biedenbender, MD, Stefan Gravenstein, MD, Jose Loera, MD, Zeba Shaheen Geloo, MD, William B Ershler, MD

Blood (2012) 120 (21): 5153.

https://doi.org/10.1182/blood.V120.21.5153.5153

Published: 2012

Journal Articles

Anemia and the Use of Erythropoietic-Stimulating Agents with Ruxolitinib in the COMFORT-II Study

Mary Frances McMullin, MD, Claire N. Harrison, DM, FRCP, FRCPath, Dietger Niederwieser, MD, Hilde Demuynck, MD, PhD, Nadja Jäckel, Andres Sirulnik, MD, PhD, Alison Wearver, PhD, Viktoriya Stalbovskaya, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Haifa Kathrin Al-Ali, MD

Blood (2011) 118 (21): 5147.

https://doi.org/10.1182/blood.V118.21.5147.5147

Published: 2011

Journal Articles

Access to Care, Race and Education Are Key Determinants of Erythropoietin Stimulating Agent (ESA) Use In Myelodysplastic Syndromes (MDS).

Amy J. Davidoff, PhD, M.S., Sheila Weiss Smith, PhD, Maria R Baer, M.D., Xuehua Ke, M.A., Jason M Bierenbaum, M.D., Franklin Hendrick, B.S., Diane L. McNally, BSPharm, M.S., Steven D. Gore, M.D.

Blood (2010) 116 (21): 3815.

https://doi.org/10.1182/blood.V116.21.3815.3815

Published: 2010

Journal Articles

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

Paul A. Hamlin, Jr, MD, Maria Alma Rodriguez, MD, Ariela Noy, MD, Carol S. Portlock, MD, David Straus, MD, Peter McLaughlin, MD, Barbara Pro, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Brett Wegner, Otilia Dumitrescu, MD, Neetha Pandit Tasker, MD, Craig H Moskowitz, MD, Andrew D Zelenetz, MD, PhD

Blood (2010) 116 (21): 1793.

https://doi.org/10.1182/blood.V116.21.1793.1793

Published: 2010

Journal Articles

Relevance of Minor PIG-A Mutations In Acquired Aplastic Anemia and Myelodysplastic Syndromes

Jeffrey J Pu, MD, Ph.D., Hetty E Carraway, MD, MBA, Rong Hu, MD, Galina Mukhina, MD, Robert A Brodsky, MD

Blood (2010) 116 (21): 4433.

https://doi.org/10.1182/blood.V116.21.4433.4433

Published: 2010

NARROW

A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease

Darbepoetin Alfa for the Treatment of Anemic Patients with Myelodysplastic Syndrome: A Belgian Single-Arm, Companion Trial to the Arcade Phase 3 Study

An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)

Erythropoiesis-Stimulating Agents in Elderly Patients with Anemia of Unknown Etiology: Treatment Response and Cardiovascular Outcomes

Treatment of a Large National Population of Anemic Hemodialysis Patients with a Long-Lasting Erythropoietin Stimulating Agent

Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)

Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis

Validation of Predictive Models for Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndromes

A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Incidence and Management of Hematological Toxicities Associated with Treatment of Hepatitis C Virus Infection in Cancer Patients

Poor ESA Responders As Defined By Week 4 Hemoglobin Response Have Greater ESA Dosing but Worse Cardiovascular Outcomes in Patients with Anemia of Chronic Kidney Disease (CKD) Not on Dialysis

Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study

Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study

The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Correction of Anemia in the Frail Elderly (CAFÉ): Results of a Randomized, Double-Blind, Placebo-Controlled Study with Darbepoetin Alfa in Elderly Patients with Chronic Unexplained Anemia

Anemia and the Use of Erythropoietic-Stimulating Agents with Ruxolitinib in the COMFORT-II Study

Access to Care, Race and Education Are Key Determinants of Erythropoietin Stimulating Agent (ESA) Use In Myelodysplastic Syndromes (MDS).

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

Relevance of Minor PIG-A Mutations In Acquired Aplastic Anemia and Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only